14.20
-0.10 (-0.70%)
| Previous Close | 14.30 |
| Open | 14.33 |
| Volume | 1,339,015 |
| Avg. Volume (3M) | 2,056,415 |
| Market Cap | 1,662,039,040 |
| Price / Sales | 11.85 |
| Price / Book | 10.88 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -140.97% |
| Operating Margin (TTM) | -87.29% |
| Diluted EPS (TTM) | -1.67 |
| Quarterly Revenue Growth (YOY) | 17.40% |
| Total Debt/Equity (MRQ) | 132.90% |
| Current Ratio (MRQ) | 2.46 |
| Operating Cash Flow (TTM) | -167.65 M |
| Levered Free Cash Flow (TTM) | -96.38 M |
| Return on Assets (TTM) | -31.14% |
| Return on Equity (TTM) | -192.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcutis Biotherapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 0.5 |
| Average | -0.70 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 113.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Mizuho, 40.85%) | Buy |
| Median | 19.00 (33.80%) | |
| Low | 18.00 (Needham, 26.76%) | Buy |
| Average | 19.00 (33.80%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 13.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Jan 2025 | 19.00 (33.80%) | Buy | 13.63 |
| 30 Dec 2024 | 19.00 (33.80%) | Buy | 14.20 | |
| Mizuho | 07 Jan 2025 | 20.00 (40.85%) | Buy | 15.76 |
| Needham | 07 Nov 2024 | 18.00 (26.76%) | Buy | 10.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WELGUS HOWARD G. | - | 14.56 | -10,000 | -145,600 |
| Aggregate Net Quantity | -10,000 | |||
| Aggregate Net Value ($) | -145,600 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.56 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WELGUS HOWARD G. | Director | 02 Jan 2025 | Automatic sell (-) | 10,000 | 14.56 | 145,600 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |